These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 15247009

  • 1. Insights into aging obtained from p53 mutant mouse models.
    Dumble M, Gatza C, Tyner S, Venkatachalam S, Donehower LA.
    Ann N Y Acad Sci; 2004 Jun; 1019():171-7. PubMed ID: 15247009
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Complicating the role of p53 in aging.
    Gentry A, Venkatachalam S.
    Aging Cell; 2005 Jun; 4(3):157-60. PubMed ID: 15924572
    [Abstract] [Full Text] [Related]

  • 4. p53: guardian AND suppressor of longevity?
    Donehower LA.
    Exp Gerontol; 2005 Jun; 40(1-2):7-9. PubMed ID: 15664727
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.
    Cao L, Li W, Kim S, Brodie SG, Deng CX.
    Genes Dev; 2003 Jan 15; 17(2):201-13. PubMed ID: 12533509
    [Abstract] [Full Text] [Related]

  • 9. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
    Ku TK, Nguyen DC, Karaman M, Gill P, Hacia JG, Crowe DL.
    Mol Cancer Res; 2007 Apr 15; 5(4):351-62. PubMed ID: 17426250
    [Abstract] [Full Text] [Related]

  • 10. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
    Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A.
    Nat Genet; 2001 Dec 15; 29(4):418-25. PubMed ID: 11694875
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Gain of function mutations in p53.
    Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ.
    Nat Genet; 1993 May 15; 4(1):42-6. PubMed ID: 8099841
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression.
    Armata HL, Garlick DS, Sluss HK.
    Cancer Res; 2007 Dec 15; 67(24):11696-703. PubMed ID: 18089799
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p53 mutation heterogeneity in cancer.
    Soussi T, Lozano G.
    Biochem Biophys Res Commun; 2005 Jun 10; 331(3):834-42. PubMed ID: 15865939
    [Abstract] [Full Text] [Related]

  • 19. Reduced hepatic tumor incidence in cyclin G1-deficient mice.
    Jensen MR, Factor VM, Fantozzi A, Helin K, Huh CG, Thorgeirsson SS.
    Hepatology; 2003 Apr 10; 37(4):862-70. PubMed ID: 12668979
    [Abstract] [Full Text] [Related]

  • 20. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia.
    Prasher JM, Elenitoba-Johnson KS, Kelley LL.
    Oncogene; 2001 May 24; 20(23):2946-55. PubMed ID: 11420707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.